2-[4-(7-Chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIβ is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model

Molecular Cancer Therapeutics

Volumn 1, Issue 14, 2002, Pages 1315-1320

  Mensah Osman, Edith J ^a   Al Katib, Ayad M ^a   Dandashi, Mahmoud H ^a   Mohammad, Ramzi M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II BETA; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; QUINOXALINE DERIVATIVE; XK 469;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL DIVISION; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; TIME; WALDENSTROEM MACROGLOBULINEMIA; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL DIVISION; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; POLY(ADP-RIBOSE) POLYMERASES; QUINOXALINES; TIME FACTORS; WALDENSTROM MACROGLOBULINEMIA;

EID: 0038042087     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Froelich-Ammon, S., and Osheroff, N. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem., 270: 21429-21432, 1995.
2. Austin, C., and Marsh, K. Eukaryotic DNA topoisomerase IIβ. BioEssays, 20: 215-226, 1998.
3. Tsutsui, K., Tsutsui, K., Sano, K., Kikuchi, A., and Tokunaga, A. Involvement of DNA topoisomerase IIβ in neuronal differentiation. J. Biol. Chem., 276: 5769-5778, 2001.
4. Negri, C., Chiesa, R., Cerino, A., Bestagno, M., Zini, N., Maraldi, N. M., and Astaldi Ricotti, G. C. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes. Exp. Cell Res., 200: 452-459, 1992.
5. Bjornsti, M., and Osheroff, N. DNA Topoisomerase protocols: DNA topology and enzymes. Methods Mol. Biol., 94/95: 253-269 and 161-195, 1999.
6. Subramanian, B., Nakeff, A., and Valeriote, F. V. Mechanism of antitumor action of a novel quinoxaline, XK469. Proc. Am. Assoc. Cancer Res., 40: 1, 1999.
7. Gao, H., Huang, K-C., Yamasaki, E. F., Chan, K. K., Chohan, L., and Snapka, R. M. XK469, a selective topoisomerase IIβ poison. Proc. Natl. Acad. Sci. USA, 96: 12168-12173, 1999.
8. Kyle, R., and Anderson, K. C. A tribute to Jan Gosta Waldenstrom. Blood, 89: 4245-4247, 1997. (Pubitemid 27260231)
9. Gobbi, P. G., Bettini, R., Montecucco, C., Cavanna, L., Morandi, S., Pieresca, C., Merlini, G., Bertoloni, D., Grignani, G., Pozzetti, U., Caporali, R., and Ascari, E. Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood, 83: 2939-2945, 1994.
10. Bender, J. C. Treatment options for indolent lymphomas. The Fellow Reporter, ASH, 42nd Annual Meeting, 6: 55-58, 2001.
11. Al-Katib, A., Mohammad, R., Hamdan, M., Mohamed, A., Dan, M., and Smith, M. Propagation of Waldenstrom's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model. Blood, 81: 3034-3042, 1993. (Pubitemid 23162123)
12. Nitiss, J. L., and Beck, W. T. Anti-topoisomerase drug action and resistance. Eur. J. Cancer, 32: 958-966, 1996.
13. Golstein, P., Ojcius, D. M., and Young, D. Cell death mechanisms and the immune system. Immunol. Rev., 121: 29-65, 1991.
14. Thompson, C. B. Apoptosis in the pathogenesis and treatment of diseases. Science (Wash. DC), 267: 1456-1462, 1995.
15. Desagher, S., Osen Sand, A., Nichols, A., Eskes, R., Montessuit, S., Lauper, S., Maundrell, K., Antonsson, B., and Martinou, J. C. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell Biol., 144: 891-901, 1999. (Pubitemid 29238966)
16. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell, 80: 293-299, 1995.
17. Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T. I., Jones, D. P., and Wang, X. Prevention of apoptosis by BCL-2: release of cytochrome c from mitochondria blocked. Science (Wash. DC), 275: 1129-1132, 1997. (Pubitemid 27097312)
18. D'Amours, D., Germain, M., Orth, K., Dixit, V. M., and Poirier, G. G. Proteolysis of poly(ADP-ribose) polymerase by caspase 3: kinetics of cleavage of mono(ADP-ribosyl)ated and DNA-bound substrates. Radiation, 150: 3-10, 1998. (Pubitemid 28285618)
19. Wall, N. R., Mohammad, R. M., and Al-Katib, A. M. Bax:Bcl-2 ratio modulation by bryostatin1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in human early pre-B acute lymphoblastic leukemia cell line, REH. Leuk. Res., 23: 881-888, 1999. (Pubitemid 29460822)
20. Lo Russo, P. M., Parchment, R., Demchik, L., Knight, J., Polin, L., Dzubow, J., Behrens, C., Harrison, B., Trainor, G., and Corbett, T. H. Preclinical antitumor activity of XK469 (NSC 656889). Invest. New Drugs, 16: 287-296, 1999. (Pubitemid 29281096)
21. LoRusso, P. M., Demchik, L., Knight, J., Polin, L., Behrens, C. H., McRipley, R., Gross, J. L., Harrison, B. A., and Corbett, T. H. Preclinical antitumor activity of XK469. Proc. Am. Assoc. Cancer Res., 35: 401, 1994.
22. Corbett, T. H., LoRusso, P., Demchik, L., Simpson, C., Pugh, S., White, K., Kushner, J., Polin, L., Meyer, J., Czarnecki, J., Heilbrun, L., Horwitz, J. P., Gro, J. L. Behrens, C. H., Harrison, B. A., McRipley, R. J., and Trainor, G. Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2- quinoxalinyloxy)phenoxy]propionat. Invest. New Drugs, 16: 129-39, 1998.